^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer

Excerpt:
We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer....The median progression-free survival was 7.7 months in the crizotinib group and 3.0 months in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001). The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001).
DOI:
10.1056/NEJMoa1214886
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Excerpt:
...- positive for the ALK fusion gene (test provided by a central laboratory)...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients

Excerpt:
...harbored ALK fusion gene and took crizotinib 3....
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Excerpt:
...resulting in echinoderm microtubule associated protein like 4 [EML4]-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay and defined by an increase in the distance between 5?...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Excerpt:
...- The institution's pre-enrollment biomarker screening at a Clinical Laboratory Improvement Amendments (CLIA) certified lab documents presence of known "sensitive" mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon 19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement; either the primary tumor or the metastatic lymph node tissue may be used for testing of mutations...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Excerpt:
...- positive for the ALK fusion gene (test provided by either a central laboratory....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Excerpt:
...These samples served as a part of negative sample set for evaluation of IHC test and/or polymerase chain reaction (PCR) to determine ALK fusion events. ...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Neoadjuvant Targeted Therapy for Resectable ALK-fusion Locally Advanced Non-small Cell Lung Cancer

Published date:
08/08/2023
Excerpt:
We enrolled 11patients from January 2019 to December 2022 at the Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute with stage IIB-IIIB ALK-positive NSCLC who received Crizotinib or Alectinib as inductive treatment strategy before surgery....All patients were confirmed clinical stage IIB-IIIB and with ALK fusion mutation. Nine patients received ALK-TKI as initial inductive treatment, among which three (patient 1, 6 and 10) received crizotinib at dose of 250 mg twice daily and six (patient 2, 4, 7, 8, 9 and 11) received alectinib at dose of 600 mg twice daily....According to the radiologic assessment before surgery, nine patients (72.7%) achieved a partial regression (PR), and two patients (patient 2 and 6) remained SD.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

P45.14 - Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China

Published date:
08/18/2021
Excerpt:
A total of 55 patients were included in the study, of which 36 with ALK fusion, and 13 with ROS1 fusion.... the ORR of crizotinib was 53% with a median PFS of 12 months (range: 1–102 months)...confirmed the therapeutic benefit of crizotinib in ALK/ROS-1fusion-positive advanced NSCLC, and also in NSCLC with MET ex14 mutation. Our data showed crizotinib is tolerable and effective, which is comparable with literature report.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Published date:
06/11/2021
Excerpt:
The study highlighted and confirmed that treatment with crizotinib led to clinical improvement in PFS among patients with advanced NSCLC with ALK fusion…
DOI:
10.1007/s40487-021-00155-3
Evidence Level:
Sensitive: C3 – Early Trials
Title:

P37.06 - Are all ALK Gene Rearrangements Created Equal??

Published date:
01/12/2021
Excerpt:
The 1-year and 2-year survival rates on crizotinib for v1 were 78.6% and 63% respectively...Patients with v2 variant were found to be prognostically superior to both v1 and v3 variants with a median PFS on crizotinib as 17.7 months, and a 1 year survival rate of 88.9% on crizotinib....Variant group V1 was found to have an overall inferior outcome with higher frequency of brain metastases when compared to V3...
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Excerpt:
Survival in 30 ALK-positive patients who were given crizotinib in the second-line or third-line setting was significantly longer than in 23 ALK-positive controls given any second-line therapy (median overall survival not reached [95% CI 14 months to not reached] vs 6 months [4–17], 1-year overall survival 70% [95% CI 50–83] vs 44% [23–64], and 2-year overall survival 55% [33–72] vs 12% [2–30]; hazard ratio 0·36, 95% CI 0·17–0·75; p=0·004).
DOI:
10.1016/S1470-2045(11)70232-7
Trial ID: